Literature DB >> 1367909

Development of a new culture system for human lymphokine-activated killer cells: comparison with a conventional static culture method.

M Murata1, T Yano, I Yoshino, M Togami, M Sogabe, K Yasumoto, K Sugimachi, G Kimura, K Nomoto.   

Abstract

We recently developed a new culture system based on dialysis perfusion (designated JCC-device) for the generation and expansion of human lymphokine-activated killer (LAK) cells (Murata et al., 1990). More recently we have scaled up the volume of the culture vessel of the JCC-device from 100 ml to 400 ml for clinical use. In the present study, using this new 400 ml JCC-device, we cultured human lymph node lymphocytes (LNL) obtained from 8 surgical patients with primary lung cancer, and investigated the cellular characteristics in comparison with a conventional batchwise culture system using tissue culture dishes. With the JCC-device, the cell density reached a maximum 2.7 x 10(7) cells/ml with greater than 90% viability by the appropriate exchange of perfusion medium and by making additions at the appropriate intervals for recombinant interleukin-2 (rIL-2). The expansion fold of LNL with the JCC-device, ranging 6.6- to 19.2-fold (mean 13.8-fold), was not significantly different from that in dish cultures. There was no marked difference in cell surface phenotypes between the two culture systems in 7 out of 8 cases. As for LAK activity of LNL, the JCC culture was either superior or equal in 4 out of 8 cases, but inferior in the other 4 cases to the conventional dish cultures. In the latter cases, the usage of serum for the JCC culture was limited, which might have resulted in the low LAK activity.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1367909     DOI: 10.1007/bf00350913

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  11 in total

1.  Characterization and modulation of human lymphokine (interleukin 2) activated killer cell induction.

Authors:  M Hoyer; T Meineke; W Lewis; B Zwilling; J Rinehart
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

2.  Generation and expansion of lymphokine-activated killer cells from lymph node lymphocytes in human lung cancer.

Authors:  T Yano; K Yasumoto; K Nomoto
Journal:  Eur J Cancer Clin Oncol       Date:  1989-02

3.  Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji).

Authors:  M A Epstein; B G Achong; Y M Barr; B Zajac; G Henle; W Henle
Journal:  J Natl Cancer Inst       Date:  1966-10       Impact factor: 13.506

4.  Cytotoxicity of a factor isolated from human spleen.

Authors:  C B Lozzio; B B Lozzio
Journal:  J Natl Cancer Inst       Date:  1973-02       Impact factor: 13.506

5.  Purification and characterization of recombinant human interleukin-2 produced in Escherichia coli.

Authors:  K Kato; T Yamada; K Kawahara; H Onda; T Asano; H Sugino; A Kakinuma
Journal:  Biochem Biophys Res Commun       Date:  1985-07-31       Impact factor: 3.575

6.  Development of a new culture system for human lymphokine-activated killer cells.

Authors:  M Murata; T Yano; M Togami; K Yasumoto; K Sugimachi; G Kimura; K Nomoto
Journal:  J Immunol Methods       Date:  1990-05-08       Impact factor: 2.303

7.  A regimen of surgical adjuvant immunotherapy for cancer with interleukin 2 and lymphokine-activated killer cells. Basis, clinical toxicity, and immunomodulatory effects.

Authors:  T Yano; T Ishida; I Yoshino; M Murata; K Yasumoto; G Kimura; K Nomoto; K Sugimachi
Journal:  Biotherapy       Date:  1991

8.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

Authors:  S A Rosenberg; M T Lotze; L M Muul; A E Chang; F P Avis; S Leitman; W M Linehan; C N Robertson; R E Lee; J T Rubin
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

9.  Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.

Authors:  W H West; K W Tauer; J R Yannelli; G D Marshall; D W Orr; G B Thurman; R K Oldham
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

10.  Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta.

Authors:  A C Ochoa; G Gromo; B J Alter; P M Sondel; F H Bach
Journal:  J Immunol       Date:  1987-04-15       Impact factor: 5.422

View more
  1 in total

1.  A new culture system for the cultivation of mammalian cells for the production of several biologically active substances.

Authors:  M Murata; M Togami; Y Tawara; K Onodera
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.